Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 9/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524329 | 1.00 | GRIA1 (0.41) | GRIA1PAOXCHRNB2CHRNB4CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL9180467 | 0.92 | HDAC6 (0.43) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL9182174 | 0.92 | HDAC6 (0.43) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL523782 | 0.88 | GRIA1 (0.40) | GRIA1PAOXCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL525824 | 0.88 | GRIA1 (0.40) | GRIA1PAOXCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL525321 | 0.85 | PAOX (0.44) | PAOXHDAC6 | |
| SCHEMBL524475 | 0.85 | PAOX (0.44) | PAOXHDAC6 | |
| SCHEMBL8778928 | 0.84 | RRM1 (0.35) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9017360 | 0.84 | GRIA1 (0.41) | GRIA1PAOXCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL526872 | 0.84 | GRIA1 (0.41) | GRIA1PAOXCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190278-A1 | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | LABORATOIRES FOURNIER SA (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2598131-A1 | COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES | Laboratoires Fournier S.A. (FR) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013884-A1 | COMPOUNDS FOR THE TREATMENT/PREVENTION OF OCULAR INFLAMMATORY DISEASES | LABORATOIRES FOURNIER SA (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190278-A1 | Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases | TNF, NFKBIA, ALDH1A2 | GRIA1 2246/4885PAOX 1954/4885CHRNB2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.